Dosing Considerations for Rufinamide in Patients With Lennox-Gastaut Syndrome: Phase III Trial Results and Real-World Clinical Data

Lennox-Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1–3]. Although the etiology of LGS is frequently unknown, the condition is characterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to control [1,3].

Seguir leyendo →
0

Dosing Considerations for Rufinamide in Patients With Lennox-Gastaut Syndrome: Phase III Trial Results and Real-World Clinical Data

Lennox-Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1–3]. Although the etiology of LGS is frequently unknown, the condition is characterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to control [1,3].

Seguir leyendo →
0

The broad spectrum of first seizure and newly-diagnosed epilepsy

The assessment of patients presenting with a first seizure (FS) is not trivial at all. This frequent clinical scenario [1] deserves an extremely careful clinical exploration and a systematic diagnostic algorithm to disentangle contributing factors, analyze individual predisposing variables, arrive at a reasonable first “working diagnosis”, and to provide the best possible counseling in a situation of huge uncertainty [2,3].

Seguir leyendo →
0
Página 177 de 194 «...150160170175176177178179...»